EPIDEMIOLOGY OF MULTIPLE MYELOMA ACCORDING TO THE КIROV REGION POPULATION REGISTERS

EPIDEMIOLOGY OF MULTIPLE MYELOMA ACCORDING TO THE КIROV REGION POPULATION REGISTERS

The aim of this study was to analyze the basic epidemiological parameters of MM in the Kirov region based on own regional population register data.Materials and methods. Five hundred and sixty-seven patients with newly diagnosed MM between 1994 and 2016 were included. The median age was 64 years (ra...

Full description

Bibliographic Details
Main Authors:	A. S. Luchinin, S. V. Semochkin, N. V. Minaeva, N. M. Pozdeev, I. V. Paramonov
Format:	Article
Language:	Russian
Published:	ABV-press 2017-10-01
Series:	Onkogematologiâ
Subjects:	multiple myeloma incidence prevalence mortality overall survival
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/258

Similar Items

Evolution of Anti-Cancer Treatment and its Impact on Surrogate Prognostic Factors in Multiple Myeloma
by: AS Luchinin, et al.
Published: (2018-04-01)

Epidemiology of multiple myeloma in city Moscow
by: O Yu Vinogradova, et al.
Published: (2019-07-01)

Epidemiology of Multiple Myeloma in Novosibirsk (Siberian Federal District)
by: NV Skvortsova, et al.
Published: (2018-12-01)

Clinical Characteristics and Risk Factors for Pleural Effusion in Patients with Multiple Myeloma
by: Kang Y, et al.
Published: (2021-02-01)

Epidemiology, Staging, and Management of Multiple Myeloma
by: Sandeep Anand Padala, et al.
Published: (2021-01-01)

Multiple myeloma in Armenia during the period 2006–2018: facts and discussion
by: Narine Ghazaryan, et al.
Published: (2021-08-01)

Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination
by: Zhenhai Li, et al.
Published: (2020-08-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma
by: Hemminki Kari, et al.
Published: (2012-10-01)

The Danish National Multiple Myeloma Registry
by: Gimsing P, et al.
Published: (2016-10-01)

Incidence and mortality of multiple myeloma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016
by: Jiangmei Liu, et al.
Published: (2019-12-01)

The importance of serum immunoglobulin free light chain assessment for predicting outcome in patients with newly diagnosed multiple myeloma in real clinical practice
by: N. V. Skvortsova, et al.
Published: (2020-10-01)

EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE
by: A. A. Solodovnik, et al.
Published: (2018-07-01)

Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population
by: Jiri Minarik, et al.
Published: (2019-09-01)

Prognostic value of the modified multiple myeloma comorbidity index in real clinical practice
by: N. V. Skvortsova, et al.
Published: (2020-10-01)

Future Directions in Maintenance Therapy in Multiple Myeloma
by: Sarah A. Holstein, et al.
Published: (2021-05-01)

What are the factors affecting survival after autologous stem cell transplantation in patients with multiple myeloma?
by: Serife Solmaz, et al.
Published: (2020-01-01)

Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis
by: Shengfeng Wang, et al.
Published: (2020-01-01)

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
by: Jian Hou, et al.
Published: (2017-07-01)

Clinical Efficacy of Daratumumab in Monotherapy of Relapsed/Refractory Multiple Myeloma
by: SS Bessmeltsev, et al.
Published: (2019-12-01)

Socioeconomic Factors and Survival of Multiple Myeloma Patients
by: Kamal Chamoun, et al.
Published: (2021-02-01)

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
by: Ilaria Saltarella, et al.
Published: (2019-01-01)

Epidemiology of geographic disparities in heart failure among US older adults: a Medicare-based analysis
by: Akushevich, I., et al.
Published: (2022)

Super-Enhancer Associated Five-Gene Risk Score Model Predicts Overall Survival in Multiple Myeloma Patients
by: Tingting Qi, et al.
Published: (2020-12-01)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
by: Qian W, et al.
Published: (2020-01-01)

EPIDEMIOLOGY AND CLINICO-DEMOGRAPHIC CHARACTERISTICS OF DIFFUSE LARGE B-CELL LYMPHOMA IN THE NOVOSIBIRSK CITY
by: E. N. Voropaeva, et al.
Published: (2021-03-01)

Cancer incidence and prevalence in Isfahan: Application of mortality data to estimates and projects for the period 2001-2015
by: Mohammad Reza Maracy, et al.
Published: (2012-01-01)

Genetic Predictors of Mortality in Patients with Multiple Myeloma
by: Hassan H, et al.
Published: (2021-04-01)

Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001–2010: a retrospective, population based analysis
by: Jon-Magnus Tangen, et al.
Published: (2018-08-01)

Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study
by: Marlies Antlanger, et al.
Published: (2018-10-01)

New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

Analysis of the effectiveness of multiple myeloma treatment based on the clinical experience of European countries
by: Vadim V. Ptushkin, et al.
Published: (2021-04-01)

The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors
by: Barry Paul, et al.
Published: (2020-08-01)

Ixazomib in the treatment of relapsed multiple myeloma
by: S. V. Semochkin
Published: (2018-07-01)

Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
by: Hájek Roman, et al.
Published: (2012-09-01)

Incidence of Multiple Myeloma in Shenyang from 2009 to 2014
by: GUAN Nannan, et al.
Published: (2019-06-01)

Natural History and Prognostic Factors at First Relapse in Multiple Myeloma
by: Chen Wang, et al.
Published: (2020-07-01)

Frequency and prognostic significance of hypercalcemia in patients with multiple myeloma
by: Kanar J Karim, et al.
Published: (2020-01-01)

Cannot write session to /tmp/vufind_sessions/sess_mr2fvu1iem4208i5l5gkqlnc0s